Speedway Scene
Markets S&P 500 7,500.58 ▲ 0.00% Nasdaq 26,517.93 ▲ 0.00% Dow Jones 44,200.00 ▲ 0.00% US 10 Yr 4.45 ▲ 0.00% Crude Oil 76.54 ▲ 0.00% Gold 2,350.00 ▲ 0.00% Bitcoin 64,000 ▲ 0.00% FTSE 100 8,400.00 ▲ 0.00% EUR/USD 1.0850 ▲ 0.00% Nikkei 225 39,000.00 ▲ 0.00%
Topic archive

Vertex Pharmaceuticals

Reporting, analysis and commentary on Vertex Pharmaceuticals from Speedway Scene, drawn together from across our coverage.

1 article Latest update: 4 Jul 2026 1 section
Related sections Health
Related topics Casgevy sickle cell children sickle cell disease CRISPR gene therapy FDA approval pediatric medicine gene editing
Tag lead
A young child with sickle cell disease receiving care in a hospital as clinicians prepare a gene-editing stem cell treatment
Health

FDA Approval of Casgevy Sickle Cell Children Opens a Cure to Kids as Young as 2

5,500 additional American children become newly eligible for a one-time cure after the FDA expanded Vertex's CRISPR therapy Casgevy to patients as young as 2 with sickle cell disease on July 1, 2026.

4 Jul 2026 ·9 min read
Keep reading

More paths through this story

This archive gathers Speedway Scene coverage of Vertex Pharmaceuticals, bringing together the reporting, analysis and commentary connected to the subject.

Related topics

Casgevy sickle cell children sickle cell disease CRISPR gene therapy FDA approval pediatric medicine gene editing Federal Reserve Donald Trump AI infrastructure semiconductors

Related sections

Health

Latest nearby

Health · 4 Jul 2026 Aetna, Cigna Headline ACA Marketplace Insurers Exit 2026 Health · 4 Jul 2026 Dead Skua Marks First H5N1 Bird Flu Australia Detection Health · 4 Jul 2026 European heatwave 20000 deaths study exposes a toll ten times official counts Health · 4 Jul 2026 Gedatolisib Breast Cancer FDA Verdict Nears for Patients Out of Options